Zura Bio Ltd. is a clinical-stage biotechnology company that engages in the development of novel medicines for immune disorders. The company is headquartered in La Jolla, California and currently employs 30 full-time employees. The company went IPO on 2021-07-16. The company is developing three assets which have completed Phase I/Ib studies. The company is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), crebankitug (ZB-168), and torudokimab (ZB-880) with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases, including systemic sclerosis and other indications with unmet needs. ZB-106 is an immunoglobulin G single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of TALTZ and tabalumab that neutralize interleukin-17A (IL-17A) and BAFF. ZB-168 is a fully human, high affinity monoclonal antibody that binds and neutralizes the IL-7 receptor chain alpha chain. ZB-880 is a fully human, high affinity monoclonal antibody that neutralizes IL-33, preventing ST2-dependent and ST2-independent inflammation.
Follow-Up Questions
Who is the CEO of Zura Bio Ltd?
Mr. Robert Lisicki is the Chief Executive Officer of Zura Bio Ltd, joining the firm since 2024.
What is the price performance of ZURA stock?
The current price of ZURA is $3.57, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Zura Bio Ltd?
Zura Bio Ltd belongs to Biotechnology industry and the sector is Health Care
What is Zura Bio Ltd market cap?
Zura Bio Ltd's current market cap is $232.4M
Is Zura Bio Ltd a buy, sell, or hold?
According to wall street analysts, 8 analysts have made analyst ratings for Zura Bio Ltd, including 5 strong buy, 6 buy, 2 hold, 0 sell, and 5 strong sell
